A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis

Tetsuji Takabayashi, Daiya Asaka, Yoshitaka Okamoto, Tetsuo Himi, Shinichi Haruna, Naohiro Yoshida, Kenji Kondo, Mamoru Yoshikawa, Yasunori Sakuma, Kunihiko Shibata, Motohiko Suzuki, Masayoshi Kobayashi, Ryo Kawata, Kenzo Tsuzuki, Mitsuhiro Okano, Takaya Higaki, Sachio Takeno, Satoru Kodama, Syuji Yonekura, Hiromi SaitoAkiyo Nozaki, Nobuyoshi Otori, Shigeharu Fujieda

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis'. Together they form a unique fingerprint.

Medicine & Life Sciences